Literature DB >> 9769329

The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

D Fishman1, G Faulds, R Jeffery, V Mohamed-Ali, J S Yudkin, S Humphries, P Woo.   

Abstract

During active disease, patients with systemic-onset juvenile chronic arthritis (S-JCA) demonstrate a rise and fall in serum interleukin-6 (IL-6) that parallels the classic quotidian fever. To investigate the possibility that this cytokine profile results from a difference in the control of IL-6 expression, we examined the 5' flanking region of the IL-6 gene for polymorphisms. A G/C polymorphism was detected at position -174. In a group of 383 healthy men and women from a general practice in North London, the frequency of the C allele was 0.403 (95% confidence interval 0.37-0.44). In comparison, 92 patients with S-JCA had a different overall genotype frequency, especially those with onset of disease at < 5 yr of age. This was mainly due to the statistically significant lower frequency of the CC genotype in this subgroup. When comparing constructs of the 5' flanking region (-550-+61 bp) in a luciferase reporter vector transiently transfected into HeLa cells, the -174C construct showed 0.624+/-0.15-fold lower expression than the -174G construct. After stimulation with LPS or IL-1, expression from the -174C construct did not significantly change after 24 h, whereas expression from the -174G construct increased by 2.35+/-0.10- and 3.60+/-0.26-fold, respectively, compared with the unstimulated level. Plasma levels of IL-6 were also measured in 102 of the healthy subjects, and the C allele was found to be associated with significantly lower levels of plasma IL-6. These results suggest that there is a genetically determined difference in the degree of the IL-6 response to stressful stimuli between individuals. The reduced frequency of the potentially protective CC genotype in young S-JCA patients may contribute to its pathogenesis. Similarly the individual's IL-6 genotype may be highly relevant in other conditions where IL-6 has been implicated, such as atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9769329      PMCID: PMC508984          DOI: 10.1172/JCI2629

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion.

Authors:  A Ray; K S LaForge; P B Sehgal
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

2.  Clinical application of IL6 in cancer therapy.

Authors:  J J Mulé; S G Marcus; J C Yang; J S Weber; S A Rosenberg
Journal:  Res Immunol       Date:  1992-09

3.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

4.  Variation in enzymatic transient gene expression assays.

Authors:  T Hollon; F K Yoshimura
Journal:  Anal Biochem       Date:  1989-11-01       Impact factor: 3.365

5.  IL-6 gene polymorphism in rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, systemic lupus erythematosus, and in healthy Danes.

Authors:  L Fugger; N Morling; K Bendtzen; L Ryder; V Andersen; C Heilman; F Karup Pedersen; J Friis; P Halbert; A Svejgaard
Journal:  J Immunogenet       Date:  1989-12

6.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.

Authors:  K Yoshizaki; T Matsuda; N Nishimoto; T Kuritani; L Taeho; K Aozasa; T Nakahata; H Kawai; H Tagoh; T Komori
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

7.  Ethnic differences in fasting plasma C-peptide and insulin in relation to glucose tolerance and blood pressure.

Authors:  J K Cruickshank; J Cooper; M Burnett; J MacDuff; U Drubra
Journal:  Lancet       Date:  1991-10-05       Impact factor: 79.321

8.  Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo.

Authors:  V Mohamed-Ali; S Goodrick; A Rawesh; D R Katz; J M Miles; J S Yudkin; S Klein; S W Coppack
Journal:  J Clin Endocrinol Metab       Date:  1997-12       Impact factor: 5.958

9.  Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis.

Authors:  F de Benedetti; M Massa; P Robbioni; A Ravelli; G R Burgio; A Martini
Journal:  Arthritis Rheum       Date:  1991-09

Review 10.  Juvenile rheumatoid arthritis: outcome and treatment for the 1990s.

Authors:  C A Wallace; J E Levinson
Journal:  Rheum Dis Clin North Am       Date:  1991-11       Impact factor: 2.670

View more
  534 in total

Review 1.  Biologic therapies in rheumatoid arthritis.

Authors:  K J Bulpitt
Journal:  Curr Rheumatol Rep       Date:  1999-12       Impact factor: 4.592

Review 2.  Type 1 and type 2 immune responses in children: their relevance in juvenile arthritis.

Authors:  L R Wedderburn; P Woo
Journal:  Springer Semin Immunopathol       Date:  1999

Review 3.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

4.  Genetic determinants of IL-6 expression levels do not influence bone loss in inflammatory bowel disease.

Authors:  C Schulte; H Goebell; H D Röher; K M Schulte
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

5.  Antagonistic pleiotropy at the human IL6 promoter confers genetic resilience to the pro-inflammatory effects of adverse social conditions in adolescence.

Authors:  Steven W Cole; Jesusa M G Arevalo; Kavya Manu; Eva H Telzer; Lisa Kiang; Julienne E Bower; Michael R Irwin; Andrew J Fuligni
Journal:  Dev Psychol       Date:  2011-07

6.  Replication and meta-analysis of the gene-environment interaction between body mass index and the interleukin-6 promoter polymorphism with higher insulin resistance.

Authors:  Patricia C Underwood; Bindu Chamarthi; Jonathan S Williams; Bei Sun; Anand Vaidya; Benjamin A Raby; Jessica Lasky-Su; Paul N Hopkins; Gail K Adler; Gordon H Williams
Journal:  Metabolism       Date:  2011-11-08       Impact factor: 8.694

Review 7.  Contact lens-related microbial keratitis: how have epidemiology and genetics helped us with pathogenesis and prophylaxis.

Authors:  F Stapleton; N Carnt
Journal:  Eye (Lond)       Date:  2011-12-02       Impact factor: 3.775

Review 8.  IL6 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review.

Authors:  Yong Yu; Wenjun Wang; Song Zhai; Shuangsuo Dang; Mingzhu Sun
Journal:  Mol Biol Rep       Date:  2012-06-20       Impact factor: 2.316

9.  A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms.

Authors:  Carolina Martínez-Laperche; Elena Buces; M Carmen Aguilera-Morillo; Antoni Picornell; Milagros González-Rivera; Rosa Lillo; Nazly Santos; Beatriz Martín-Antonio; Vicent Guillem; José B Nieto; Marcos González; Rafael de la Cámara; Salut Brunet; Antonio Jiménez-Velasco; Ildefonso Espigado; Carlos Vallejo; Antonia Sampol; José María Bellón; David Serrano; Mi Kwon; Jorge Gayoso; Pascual Balsalobre; Álvaro Urbano-Izpizua; Carlos Solano; David Gallardo; José Luis Díez-Martín; Juan Romo; Ismael Buño
Journal:  Blood Adv       Date:  2018-07-24

10.  Cytokine gene polymorphisms associated with symptomatic parvovirus B19 infection.

Authors:  J R Kerr; M McCoy; B Burke; D L Mattey; V Pravica; I V Hutchinson
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.